Healthcare Industry News: skin cancer
News Release - June 1, 2009
Introducing The Pioneering XTRAC Velocity Excimer Laser: Delivers Psoriasis And Vitiligo Treatments Three Times FasterBreakthrough Device Can Cover a Significantly Higher Percentage of a Person’s Body Surface Per Session, Providing Practical Alternative to Pharmaceuticals, Biologics or Full-Body Phototherapy
MONTGOMERYVILLE, Pa.--(HSMN NewsFeed)--PhotoMedex, Inc. (NASDAQ: PHMD ), a leader in the development of proprietary excimer laser and fiber optic systems as well as other products for dermatological applications, today announced the availability of its groundbreaking XTRAC Velocity™ Excimer Laser, a device expected to redefine laser treatment options for patients suffering from psoriasis and vitiligo.
Two separate independent third-party agencies have confirmed that the XTRAC Ultra® laser, precursor to the XTRAC Velocity excimer laser, is the most accurate, powerful, and fastest excimer laser available to date. PhotoMedex has raised the bar even higher with the Velocity laser, which features an average laser power of up to 7.2 watts delivered to the patient. Velocity’s treatment time is nearly three times faster than PhotoMedex’ XTRAC Ultra laser. In performance tests the device has been able to treat lesions of 3,500 cm2 (600 mj/cm2) in 4 minutes, 52 seconds*—roughly 1/3 the time required by the Ultra.
Because the innovative Velocity excimer laser can cover a much greater surface area in the average treatment session—up to 20% of the body surface in five minutes versus only 2 to 4% for alternative lasers—it is the first practical alternative to potent pharmaceuticals or full-body UV irradiation for patients with severe psoriasis.
“The XTRAC Velocity laser is going to be a game-changer for patients and dermatology practices alike,” said Jeff O’Donnell, president of PhotoMedex. “For patients, the Velocity will dramatically shorten treatment times, increase the size and number of lesions that can be treated per session, and open laser therapy as a viable alternative for patients who were not necessarily laser candidates in the past. In fact, for busy dermatology practices, the Velocity will make it practical to treat as many as 32 patients per day.”
New Touchscreen, Handpiece Controls
With a maximum repetition rate of 400 Hz and delivered laser energy of 12 to 18 millijoules/pulse, PhotoMedex’ XTRAC Velocity is unparalleled in its power and treatment speed. The new laser system has an unparalleled safety profile and is also highly effective with a long duration of remission—yet laser performance is only the beginning of the unit’s advantages.
To increase quality of care for patients as well as increase the clinician’s convenience, the Velocity offers a new full-color touchscreen control interface. The screen and built-in database tracking software goes beyond normal equipment operation to incorporate patient information including ID generation, recognition, treatment history, dosing heuristics and more. Also included for the first time on the Velocity is a touch control handpiece that allows the laser treatment to be delivered more easily compared to conventional footswitch-controlled devices.
“Profit Per Treatment” Model
Like all the excimer lasers in the PhotoMedex line, the Velocity is available to clinics at no direct cost via a unique consignment-based business model. Thanks to the “Profit per Treatment” model, dermatologists provide Velocity laser therapy to their customers, paying a fee only on treatments rendered. In-service training is provided by a dedicated PhotoMedex clinical specialist. Reimbursement support is also provided by a team of direct employee-insurance specialists who continue to receive positive reviews from both office staff and patients for their dedicated and knowledgeable support. Purchase options and financing for PhotoMedex lasers are available as well.
For full details about the new PhotoMedex XTRAC Velocity excimer laser, call 1-877-44-XTRAC or email firstname.lastname@example.org.
* Treatment time calculations do not include the overhead associated with moving the hand piece.
PhotoMedex offers a wide range of products and services across multiple specialty areas, including dermatology, urology, gynecology, orthopedics and other surgical specialties. PhotoMedex is a leader in the development, manufacturing and marketing of medical laser products and services. PhotoMedex also develops and markets products based on its patented, clinically proven Copper Peptide technology for skin health, hair care and wound care. PhotoMedex sells directly to dermatologists, plastic and cosmetic surgeons, spas and salons and through licenses with strategic partners into the consumer market, including a long-term worldwide license agreement with Neutrogena™, a Johnson & Johnson company. ProCyte brands include Neova™, Ti-Silc™, VitalCopper™, Simple Solutions™ and AquaSante™.
In addition, as a result of the recent merger with Photo Therapeutics, PhotoMedex now researches, develops and manufactures non-laser light devices for the treatment of clinical and aesthetic dermatological conditions and adds the Omnilux™ products to its arsenal. The Omnilux™ products incorporate a new technology based on narrowband Light Emitting Diodes (LEDs) to treat a wide range of dermatological conditions including acne, photodamage, skin rejuvenation, psoriasis, post-surgery wound healing and non-melanoma skin cancer.
Safe Harbor Statement
Some portions of this release, particularly those describing PhotoMedex’ strategies contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1993, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While PhotoMedex is working to achieve those goals, actual results could differ materially from those projected in the forward-looking statements as a result of a number of factors, including difficulties in marketing its products and services, need for capital, competition from other companies and other factors, any of which could have an adverse effect on the business plans of PhotoMedex, its reputation in the industry or its results. In light of significant uncertainties inherent in forward-looking statements included herein, the inclusion of such statements should not be regarded as a representation by PhotoMedex or its subsidiaries that the forward-looking statements will be achieved.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.